Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.33 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374581 | 1.00 | PTGS2 (0.38) | PTGS2DRD2DRD3KCNH2IDO1 | |
| SCHEMBL3376061 | 1.00 | PTGS2 (0.38) | PTGS2DRD2DRD3KCNH2IDO1 | |
| SCHEMBL3376060 | 1.00 | PTGS2 (0.38) | PTGS2DRD2DRD3KCNH2IDO1 | |
| SCHEMBL3378207 | 0.94 | SLC2A1 (0.34) | PTGS2DRD2DRD3KCNH2SLC2A1 | |
| SCHEMBL3377824 | 0.86 | SLC2A1 (0.36) | KCNH2IDO1SLC2A1CDK9NFE2L2 | |
| SCHEMBL3377827 | 0.86 | SLC2A1 (0.36) | KCNH2IDO1SLC2A1CDK9NFE2L2 | |
| SCHEMBL3377820 | 0.86 | SLC2A1 (0.36) | KCNH2IDO1SLC2A1CDK9NFE2L2 | |
| SCHEMBL3377688 | 0.86 | SLC2A1 (0.36) | KCNH2IDO1SLC2A1CDK9NFE2L2 | |
| SCHEMBL3373217 | 0.77 | CRHR1 (0.36) | DRD2DRD3KCNH2IDO1CDK9 | |
| SCHEMBL3452969 | 0.77 | CRHR1 (0.36) | DRD2DRD3KCNH2IDO1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | claimed |
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | PTGS2 2880/4885DRD2 323/4885DRD3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.